HC Wainwright began coverage on shares of Aura Biosciences (NASDAQ:AURA – Free Report) in a research report report published on Thursday, Marketbeat Ratings reports. The brokerage issued a buy rating and a $21.00 price objective on the stock.
Aura Biosciences Stock Up 0.9 %
AURA stock opened at $10.36 on Thursday. Aura Biosciences has a twelve month low of $5.99 and a twelve month high of $12.44. The company has a market cap of $513.23 million, a PE ratio of -5.57 and a beta of 0.38. The business’s 50-day simple moving average is $7.69 and its 200 day simple moving average is $7.83.
Aura Biosciences (NASDAQ:AURA – Get Free Report) last released its earnings results on Thursday, May 9th. The company reported ($0.40) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.51) by $0.11. On average, equities research analysts anticipate that Aura Biosciences will post -1.8 EPS for the current year.
Institutional Investors Weigh In On Aura Biosciences
Aura Biosciences Company Profile
Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.
See Also
- Five stocks we like better than Aura Biosciences
- What is a Bond Market Holiday? How to Invest and Trade
- Is Crypto Cool Again? What Stocks You Should Be Watching
- How to Most Effectively Use the MarketBeat Earnings Screener
- Why Call Options Volume for These 2 Stocks Spiked Together
- Market Cap Calculator: How to Calculate Market Cap
- MarketBeat Week in Review – 7/22 – 7/26
Receive News & Ratings for Aura Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aura Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.